Background: Ischaemic stroke is a common complication of atrial fibrillation (AF). Cardiology societies recommend assessing the risk of ischaemic stroke and using adequate prevention in patients with AF. Currently, oral anticoagulants and antiplatelet drugs are the most commonly used methods of stroke prevention. Left atrial appendage (LAA) is thought to be the main source of thrombi in patients with AF. LAA closure procedures that have been recently introduced into the clinical practice are an alternative method of stroke prevention in patients with contraindications to oral anticoagulants or with a high risk of bleeding. Two systems of percutaneous LAA closure are currently available, the Watchman plug and the Amplatzer Cardiac Plug, but experience with these procedures is still very limited.
INTRODUCTION
Atrial fibrillation (AF) is the most common supraventricular arrhythmia occurring in 1-2% of the general population. Prevalence of this arrhythmia continues to rise and the number of patients with AF has been estimated to increase 2.5-fold (to 5.6 million in the United States) by 2050 [1] .
The presence of AF is associated with a 2-fold increase in all-cause mortality. In addition, AF leads to many complications including stroke which is one of the most dangerous sequelae of AF and a major cause of mortality in this patient group [2] . Published data indicate that AF is associated with a 5-fold increase in the risk of stroke [3] . Stroke due to AF results in a nearly twice higher mortality and more severe disability due to permanent neurological deficits compared to stroke of other aetiology. It is also associated with an increased risk of recurrent stroke [4] .
According to the current European Society of Cardiology guidelines, oral anticoagulant (OAC) therapy is indicated in all patients at high risk of thromboembolic complications as estimated by the CHADS2/CHA2DS2VASc score [5] . Until recently, vitamin K antagonists were mainly used for this purpose but it has been shown that with this therapy, the international normalised ratio (INR) is kept within the therapeutic range (2.0-3.0) for only about 60% of the treatment time [6] [7] [8] .
In addition, both warfarin and newer oral anticoagulants (dabigatran, rivaroxaban, apixaban) increase the risk of severe bleeding complications (about 2-3% per year), and the rate of intracranial haemorrhages associated with anticoagulant therapy is about 0.1-0.5% per year, depending on the drug used [9, 10] . Thus, a continued search for new methods for stroke prevention in patients with AF seems justified.
Development of thrombi in the left atrium is a key factor in the pathogenesis of stroke related to AF. Using transoesophageal echocardiography, it has been shown that the major source of embolic material in patients with AF is the left atrial appendage (LAA) [11, 12] . It has been estimated that 90% of thrombi responsible for ischaemic strokes in these patients originate from LAA [12] .
Among newer methods of ischaemic stroke prevention in AF, percutaneous LAA closure procedures have been introduced as a possible alternative to drug therapy. Initial clinical experience, also including some Polish centres, was gathered with the PLAATO system [13] [14] [15] . Despite promising results, however, this system was removed from the market due to commercial reasons. Two systems of percutaneous LAA closure are currently available, Watchman and Amplatzer Cardiac Plug (ACP). A randomised study (PROTECT--AF) was undertaken with the use of Watchman plug [16] , while the literature data regarding ACP are limited but it is the latter method that allows immediate withdrawal of OAC therapy by complete occlusion of the LAA entry with an additional disk.
The aim of this study was to evaluate safety and feasibility of percutaneous LAA closure with ACP in patients with nonvalvular AF and multiple comorbidities resulting in a high risk of stroke and bleeding complications.
METHODS

Study group
We evaluated consecutive 21 patients aged 18 years and above with documented AF, regardless of gender. The inclusion criteria were as follows: Left atrial appendage occlusion was performed with the use of the ACP device. This device consists of two main parts: a lobe with small hooks which is the main fixating component preventing any subsequent dislocation of the device, and a proximally located disk. The purpose of the disk is to provide tight occlusion of the LAA entry (Fig. 1) . The disk is connected to the lobe by a flexible waist that allows the disk to be tilted in relation to the lobe. This allows optimal adjustment of the disk to the LAA entry plane and thus providing tight occlusion. The device may be used to occlude a LAA that is at least 1 cm deep.
Amplatzer Cardiac Plug implantation procedure
The procedure of ACP implantation was preceded by intravenous administration of 500 mL of normal saline to provide nephroprotection, and 1 g of cephazoline as a measure to prevent bacterial endocarditis. In addition, all patients who were not receiving antithrombotic therapy at the time of procedure were administered a loading dose of acetylsalicylic acid (300 mg) and clopidogrel (300 mg) at least 2 hours before the procedure. Continued acetylsalicylic acid therapy was recommended for at least 6 months, and clopidogrel therapy (75 mg/day) for 1-3 months, unless other indications for the use of these drugs were also present.
Implantation procedures were performed under general anaesthesia with transoesophageal echocardiographic and fluoroscopic guidance.
Stage I: Transseptal puncture. Transseptal puncture was performed using standard equipment including the Brockenbrough needle and a 8 F SL0 St. Jude Medical transseptal sheath. The puncture was guided by transoesophageal echocardiography and left atrial pressures and performed in the middle lower part of the septum. This puncture site is recommended for both safety reasons and the ease of reaching LAA with the guiding system. In echocardiography, the septum was imaged in two perpendicular planes, a bicaval view and an aortic short-axis view (Fig. 2) . After transseptal puncture and introduction of the system to the left atrium, unfractionated heparin was administered in an initial dose of 1000 U/ /10 kg of body weight to increase the activated clotting time to at least 250 s.
Stage II. Following transseptal puncture, the sheath was introduced into LAA using a guidewire. Angiography was performed with manual contrast agent administration in at least two perpendicular planes (right and left anterior oblique views). Based on these images, LAA anatomy was determined and the largest LAA dimension was measured (Fig. 3) . Independent from the angiographic evaluation, LAA entry dimension was also evaluated at this stage in multiple planes by transoesophageal echocardiography (Fig. 4) . The size of an implanted ACP device was chosen depending on the maximum measured LAA neck width: for LAA neck sizes up to 22 mm, an ACP device oversized by 2 mm was used, and a device oversized by 4 mm was used for LAA neck sizes above 22 mm. After LAA angiography, the transseptal sheath was replaced with the ACP introduction system which was placed in LAA.
Stage III: The ACP system was prepared and introduced into LAA using the sheath. The tip of the introduction system was placed at mid-depth of the appendage. Then, an appropriately sized ACP device was introduced under fluoroscopic and echocardiographic guidance (2-chamber view) to allow expansion of the ACP lobe perpendicularly to the LAA long axis. When the position of the ACP lobe and its stability were confirmed, the introduction system was removed, releasing the ACP disk (Figs. 5A, B) .
Stage IV. Before the introduction system was released, an appropriate position of the ACP device in the LAA neck entry was evaluated, along with the effectiveness of LAA occlusion (Figs. 6, 7) . Postprocedural evaluation of the ACP device position included its stability and appropriate location in relation to the mitral valve and the left circumflex coronary artery. In addition, the pericardium was checked for any effusion during the procedure.
A successful LAA closure was defined as no flow distal to the ACP disk or trace flow between the disk and the lobe by angiographic and echocardiographic evaluation. During ho- Figure 7 . Figure 7 . Figure 7 . Figure 7 . Figure 7 . Echocardiographic evaluation following Amplatzer Cardiac Plug device deployment precluding tight occlusion of the appendage). In 90% of successful procedures (18 patients), LAA closure was possible with the initially chosen device size. In 2 patients, the device size had to be changed (for a smaller sized device in 1 patient, and a larger sized device in the other patient).
Total procedure duration, fluoroscopy time, and the amount of contrast agent administered are shown in Table 4 . A serious periprocedural complication occurred in 1 (4.76%) patient who had cardiac tamponade requiring pericardiocentesis. This adverse event likely occurred to left atrial wall damage during withdrawal of the ACP introduction system. In addition, clinically and haemodynamically insignificant pericardial effusion that required no intervention was noted in 2 (9.5%) patients (Table 5 ). Other types of periprocedural complications reported in the literature, including stroke, ACP dislocation, ACP thrombosis, and coronary artery air embo- spitalisation, echocardiography to check for any pericardial effusion was repeated twice, first within several hours after the procedure and then before hospital discharge. Evaluation of ACP implantation safety included the following adverse events: death, cardiac tamponade, pericardial effusion requiring follow-up and prolonged hospitalisation, stroke, device embolisation, device dyslocation, and coronary artery air embolism.
RESULTS
The study group included 14 men and 7 women. Mean patient age was 71 years, and one third of patients were above 75 years of age. The study population included patients at increased risk of both thromboembolic and bleeding complications, with the mean CHA2DS2VASc score of 4.43 points, and the mean HAS-BLED score of 3 points (Table 1) . Table 2 shows comorbidities in the study group. A majority of the study group were patients with low left ventricular ejection fraction and chronic heart failure -9 patients, including 6 patients with a cardiac resynchronisation therapy defibrillator (CRT-D) device, and 3 patients with an implantable cardioverter-defibrillator (ICD). In addition to these patients, an ICD or CRT-D had also been implanted in 2 subjects, including for primary prevention of a sudden cardiac death in 1 patient, and for secondary prevention of a sudden cardiac death in 1 patient with hypertrophic cardiomyopathy.
The mean LAA neck diameter by transoesophageal echocardiography was 20.3 ± 4.2 mm (min. 14 mm, max. 28 mm). Similarly, the mean LAA neck diameter as measured by LAA angiography was 20.7 ± 3.8 mm (min. 14 mm, max. 28 mm). The implanted ACP device size ranged from 16 mm to 30 mm (Table 3) .
Successful LAA closure was obtained in 20 (95.2%) patients. In 1 patient, optimal effect of the procedure was not possible due to anatomical reasons (an additional LAA lobe lism, were not noted in patients undergoing ACP implantation in our centre. DISCUSSION Despite several years of experience with different percutaneous LAA closure systems, this form of stroke prevention in patients with nonvalvular AF has not become widely adopted. Unresolved issues include lack of data on optimal patient selection, risk of periprocedural complications, and a possibility of incomplete LAA closure. Residual LAA flow after implantation of the Watchman plug is a common phenomenon found in 32% of patients, although it has not been shown to increase the rate of thromboembolic complications [17] . In contrast, the ACP device uses an additional disk occluding LAA entry and thus potentially allows a higher rate of complete closure. However, this system has been the most recent one to be introduced clinically and thus its safety and effectiveness still require evaluation.
The only prospective, randomised, multicentre study that evaluated the effectiveness and safety of LAA closure was the Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation (PROTECT AF) trial. This study evaluated the effectiveness and safety of LAA closure using the Watchman device as compared to warfarin therapy. The study included 707 patients, with 463 of them randomised to implantation of a Watchman plug. It was shown that the effectiveness of stroke prevention using the Watchman device is noninferior to warfarin therapy, but with a significantly lower risk of bleeding complications [16] . However, the combined safety endpoint that included both bleeding complications and periprocedural complications occurred significantly more commonly among patients in the Watchman plug implantation group than in the warfarin group (7.4 vs. 4.4 per 100 patient-years). In the intervention group, the most common safety endpoint was cardiac tamponade requiring percutaneous or surgical drainage (4.8% patients). Other safety endpoints included periprocedural strokes (1.1%) and implant embolisation (0.6%). Overall, major complications occurred in 6% of patients undergoing invasive treatment in the PROTECT AF study.
Our results on ACP implantation may be compared with only two other ACP registries: a European registry that included 143 patients and an even smaller, two-center Asia-Pacific experience registry including 20 patients [18, 19] . In the first of these registries, successful LAA closure was obtained in 96% of cases, and in the other in 19 of 20 patients (95%). In our study group, ACP deployment resulted in successful LAA closure in 20 of 21 patients (95.2%). These results are in agreement with the literature data and indicate that these procedures may be performed with a relatively high success rate.
When evaluating percutaneous LAA closure using ACP, a factor of equal importance to its effectiveness is the analysis of procedural safety. Data on the rate and type of complications occurring with this type of procedure are crucial for determining the criteria of patient selection for ACP implantation. In our opinion, decisions regarding patient selection for this treatment should be ultimately based on both the estimated risk of stroke and bleeding complications and the risk of periprocedural complications. Unfortunately, heterogeneity regarding stroke and bleeding risk in various registries and studies precludes direct comparisons, both in regard to ACP implantation outcomes in particular studies and in terms of comparing ACP implantation safety with that of the Watchman plug.
Park et al. [18] in an analysis of patients undergoing LAA closure using ACP who were included in the European regi- Table 3 . Table 3 . Table 3 . Table 3 . Table 4 . Table 4 . Table 4 . Table 4 . stry showed a similar rate of serious periprocedural complications (7%). Similarly to the PROTECT AF study, the most common adverse events were cardiac tamponade (4%) and periprocedural stroke (2%), followed by air embolism with transient ST segment elevation (1%), device embolisation (1%), and the loss of implant in the venous system (1%) [18] . In the Asia-Pacific experience registry, complications occurred in 3 of 20 patients (15%) and included a thrombus precluding ACP implantation, coronary artery embolisation, and oesophageal injury [19] . In our patients, complication rate was 4.76%, similar to the literature data regarding both the Watchman plug and ACP. Complication rate clearly reduces with growing operator experience. Both our findings and the Asia-Pacific experience registry are early results obtained during initial implantations, while the PROTECT AF study and the European registry reported on data collected in centres which performed many more implantation procedures. The importance of the learning curve has also been highlighted by the Continued Access Registry (CAP) findings, reporting on consecutive 460 patients who underwent Watchman plug implantation in centres previously participating in the PRO-TECT AF study [20] . This registry showed not only a higher implantation success rate of 95% but also a lower periprocedural complication rate which was less than 3.7% (including cardiac tamponade in 2.2% of patients and no cases of stroke). Also in the PROTECT AF study, early complication rate was higher compared to the later period of the study (10% vs. 5.5%, respectively).
Results of ACP implantation are also affected by the clinical characteristics of the treated patients. The PRO-TECT AF study population included patients with at least 1 point in the CHADS2 score, and those were not necessarily patients with contraindications to anticoagulant treatment. As many as 33.9% of patients who underwent Watchman plug implantation had only 1 point in the CHADS2 score, corresponding to an annual stroke rate of only 2.8%. In addition, the study protocol called for 45--day OAC therapy following device implantation. The European registry findings on ACP implantation also relate to an unselected patient population, as this treatment approach was considered an alternative to warfarin therapy in the participating centres. Unfortunately, the report by Park et al. [18] gave no information about the CHADS2/ /CHA2DS2VASc scoring as well as comorbidities in the study population, thus precluding precise comparisons of patient outcomes and benefits between various studies. Patients in the Asia-Pacific experience registry were a more selected population, as this registry included patients with at least 1 point in the CHADS2 score and one of the following: bleeding requiring treatment or follow-up, labile INR values, transient ischaemic attacks occurring during warfarin treatment, or refusal of warfarin treatment.
Our study population included much more sicker patients, as evidenced by a high mean CHA2DS2VASc score of 4.43 ± 1.4 points. In addition, these patients were characterised by not only a high stroke risk but also a high bleeding risk, with the HAS-BLED score of ≥ 3 points (or lower HAS-BLED risk but with contraindications to OAC such as previous central nervous system bleeding or skin necrosis). Beside stroke and bleeding risk, a much higher comorbidity burden in our study population is also evidenced by a large proportion of patients with heart failure and an implanted defibrillator (either CRT-D or ICD; 11 patients). Despite this, the rate of major complications in our study population was rather low.
CONCLUSIONS
Based on our experience, successful LAA occlusion using the ACP device is feasible in most patients with multiple comorbidities and a high risk of stroke and bleeding complications. The rate of serious periprocedural complications related to ACP implantation has been relatively low among these patients. Taking into account potential complications, patient selection for this procedure should be based on careful evaluation of benefits of the invasive prevention approach, including the risk of stroke and bleeding complications when alternative strategies are used.
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